SignalMacro
U.S. IPO Weekly Recap: Trickle Of Biotech Activity Continues Amid Tech Sell-Off
Biotech IPO activity persists despite tech sell-off, signaling sector resilience.
Context
What happened: One biotech IPO debuted this week while four IPOs submitted initial filings, including two sizable biotech filings. Allergy and autoimmune biotech Lycia Therapeutics (LYCA) priced its upsized IPO at the top of the range.
Why it matters: The activity continued a trickle of biotech IPO activity during a tech sell-off, with two sizable biotech filings among the new submissions.
What changed
One biotech IPO debuted this week while four IPOs submitted initial filings, including two sizable biotech filings. Allergy and autoimmune biotech Lycia Therapeutics (LYCA) priced its upsized IPO at the top of the range.
Why it matters
The activity continued a trickle of biotech IPO activity during a tech sell-off, with two sizable biotech filings among the new submissions.